What is the role of the (1 → 3)-β-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation?

Mycoses

Volumn 56, Issue 1, 2013, Pages 34-38

  Metan, Gökhan ^a   Koc A N ^a   Kaynar, Leyla G ^a   Atalay, Altay ^a   Öztürk, Ahmet ^a   Eser, Bülent ^a   Çetin, Mustafa ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

1,3 beta d glucan; Autologous haematopoietic stem cell transplant; Candidiasis; Diagnosis of invasive fungal infection; Invasive aspergillosis

Indexed keywords

(1-3) BETA DEXTRO GLUCAN; AMPHOTERICIN B; ARABINOSIDE; CASPOFUNGIN; CYTOSINE; ETOPOSIDE; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MELPHALAN; POLYSACCHARIDE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CULTURE; BLOOD SAMPLING; CASE REPORT; CHORIOCARCINOMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INVASIVE ASPERGILLOSIS; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING;

ADULT; AGED; BETA-GLUCANS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871620820     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02195.x     Document Type: Article

References (21)

1. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
2. Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007; 35: 421-7.
3. Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 2009; 43: 121-6.
4. Bow EJ. Invasive fungal infections in heamatopoetic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint. Mycopathologia 2009; 168: 283-97.
5. Marty FM, Koo S. Role of (1-->3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47(Suppl. 1): S233-40.
6. De Pauw B, Walsh TJ, Donnelly JP et al. revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
7. Cuenca-Estrella M, Bassetti M, Lass-Florl C, Racil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66(Suppl. 1): i15-24.
8. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750-70.
9. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using 1, 3-{beta}-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
10. Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-36.
11. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of (1, 3)-beta-d-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-9.
12. Senn L, Robinson JO, Schmidt S et al. 1, 3-Beta-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85.
13. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
14. Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49: 1688-93.
15. Rubio PM, Sevilla J, Gonzalez-Vincent M et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study. J Pediatr Hematol Oncol 2009; 31: 642-6.
16. Metan G, Koc AN, Atalay A et al. What should be the optimal cut-off of serum 1, 3-β-d-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies? Scand J Infect Dis 2011. DOI: 10.3109/00365548.2011.638319
17. Nagasawa K, Yano T, Kitabayashi G et al. Experimental proof of contamination of blood components by (1, 3)-beta-d-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 2003; 6: 49-54.
18. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1, 3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50: 3450-3.
19. Metan G, Agkus C, Buldu H, Koc AN. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1, 3-beta-d-glucan in patients without risk factors for invasive fungal infections. Infection 2010; 38: 217-21.
20. Metan G, Agkus C, Nedret Koc A, Elmali F, Finkelman MA. Does ampicillin-sulbactam cause false positivity of (1, 3)-beta-d-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses 2011. doi: 10.1111/j.1439-0507.2011.02131.x. [Epub ahead of print]
21. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-beta-d-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1.